Keyword: AstraZeneca

We caught up with Tony Johnson, CEO at Goldfinch Bio, and discussed why investment and development in kidney disease has lagged.

Pro-Remain politicians saw the reiteration of an old position as evidence that the split from the U.K. will decimate life science research.  

AstraZeneca dropped mGluR5 antagonist AZD2066 after getting a look at midphase data, but Sinntaxis thinks it has potential in stroke patients.

Early data showed that Blueprint's RET inhibitor and AstraZeneca’s Tagrisso could potentially beat treatment resistance in NSCLC patients.

FibroGen’s partner Astellas has reported phase 3 data that could support filings of their HIF inhibitor in Europe as an oral alternative to EPO.

AstraZeneca plans to use AI and apps to help its operations in China become a broader provider of healthcare services, CEO Pascal Soriot told Reuters.

Gene-editing specialist Horizon Discovery has entered into a collaboration with AstraZeneca to set up a genomics discovery platform.

Different KRAS mutations exert diverging effects on protein function, a new study illustrates.

4D Molecular Therapeutics raised $90 million in funding, with plans to advance into clinical trials through its partners AstraZeneca and Roche.

The deal follows a midphase trial that linked oral myeloperoxidase inhibitor AZD3241 to numerical improvements on a scale of MSA symptoms.